Short, Simple Treatment. Lasting Lung Health.

The dNerva® Lung Denervation System is novel, catheter-based system used to treat overactive airway nerves in a procedure called Targeted Lung Denervation. This first-of-its kind technology addresses underlying COPD pathophysiology to help preserve lung health.1,2

Targeted Lung Denervation

Disrupting Pulmonary Nerve Input

Targeted Lung Denervation (TLD) is a non-surgical, outpatient procedure that involves passing the specialized, dNerva Catheter through a flexible bronchoscope to complete a full circumferential ablation in the main bronchi of each lung.

The ablation permanently disrupts pulmonary nerve input to the lung to reduce the clinical consequences of neural hyperactivity.

Non-Surgical, Outpatient Treatment

The Procedure

Step 1: Position

The dNerva Catheter threads through the working channel of the bronchoscope and is positioned in the main bronchi.

Step 2: Inflation

The conduit and balloon are inflated by circulating the coolant through the catheter which brings the electrode in contact with the airway wall.

Step 3: Confirmation

Confirm good contact of the electrode with the airway wall and that adequate distance from the esophagus is achieved.

Step 4: Activation

Activation of the radio-frequency energy lasts approximately 2 minutes per position. Each bronchus is treated four times to complete circumferential ablation.


The procedure will last about 60 minutes and patients can expect to go home the same day. Post-procedure follow-up care is consistent with advanced bronchoscopic procedures.

Reducing Neural Hyperactivity

How it Works

The natural release of acetylcholine in COPD patients occurs when the brain signals the lung, via the vagus nerve, and moves the pulmonary system to a state of heightened neural activity which is associated with chronic airway inflammation, increased exacerbations and symptom burden. 3,24

Anticholinergic Drugs
Current anticholinergic drug therapies attempt to block the binding of acetylcholine in the lungs, helping to reduce COPD symptoms. However, these therapies are not always effective at preventing severe symptoms or exacerbations.

Targeted Lung Denervation
Disruption of vagus nerve signaling as a result of TLD, can durably reduce acetylcholine release, and therefore, keeps the pulmonary system in a state of reduced neural activity.

Anticholinergic Drugs
Anticholinergic Drugs
Targeted Lung Denervation
Targeted Lung Denervation

Before & After Slider

The dNerva Difference

With less acetylcholine release, the airway smooth muscle relaxes and mucous secretion decreases moving the pulmonary system to a state of “low alert”. This has the potential to reduce exacerbation risk, improve COPD symptoms and stabilize lung function over time.

dNerva Before
dNerva After

Discover our Products

dNerva Lung Denervation System

The dNerva Lung Denervation System is comprised of two parts: The Nuvaira Console and the dNerva Catheter.

dNerva Lung Denervation System

Nuvaira Console

The Nuvaira Console includes a thermoelectric plate and pump that cools the fluid circulating through the dNerva catheter to protect the airway wall during Radio-frequency energy delivery. The Nuvaira Console also includes graphical user interface with a prompt screen to control the console and guide the user.

dNerva Lung Denervation System

dNerva Catheter

The dNerva Catheter is a specialized, patented disposable component that is compatible with most flexible bronchoscopes utilizing working channels down to 2.8mm in diameter. The distal balloon and electrode assembly have been designed to collapse to fit through the bronchoscope’s working channel.

dNerva Lung Denervation System

Design Features

Cooling to Protect Airway Walls

During inflation of the dNerva Catheter, coolant flows underneath the electrode and through the catheter balloon which cools and protects the inner surface of the airway wall while focusing heating at depth.

Catheter Sizing

Four dNerva Catheter models can accommodate a broad range of bronchi sizes.

dNerva Lung Denervation System


≥ 9mm – 12mm


≥ 11.5mm – 14mm


≥ 13.5mm – 16.5mm

Extra Large

≥ 16.0mm – 20mm

COPD Exacerbations are the Problem.
Be a Part of the Solution.

The AIRFLOW-3 Clinical Trial is the first interventional COPD trial targeting exacerbation risk reduction in patients on optimal drug therapy.